Kodiak Sciences' Zenkuda Phase 3 GLOW2 trial shows superiority in diabetic retinopathy
Kodiak Sciences' Zenkuda Phase 3 GLOW2 trial shows superiority in diabetic retinopathy, supports multi-indication BLA-ready profile and accelerated filing plans
- Phase 3 GLOW2 topline analysis showed Zenkuda (tarcocimab tedromer) superiority versus sham in diabetic retinopathy.
- Zenkuda demonstrated a favorable safety profile in GLOW2, supporting development across multiple indications.
- Kodiak Sciences plans to accelerate its BLA submission timeline for Zenkuda based on the GLOW2 results.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.